Zevra Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with rare diseases and complex disorders
The company leverages advanced scientific research to address unmet medical needs, particularly in the areas of neurological and metabolic conditions. Through its commitment to cutting-edge innovation and patient-centered solutions, Zevra Therapeutics aims to improve the quality of life for individuals affected by challenging health conditions, fostering hope and enhancing treatment options in the biotech landscape.
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic Metabolic Diseases Advisory Committee.
FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare disease portfolio. Key decisions and market opportunities ahead in 2024.
Investors seeking promising opportunities in the biotech and tech sectors should keep an eye on several companies showing potential for significant market turnarounds. Recent upticks in stock prices suggest these companies could be on the cusp of substantial growth. Here's a closer look at some of these emerging players:
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.
Zevra Therapeutics (NASDAQZVRA), a rare disease therapeutics company, uniquely combines data-driven techniques, patient needs and outside the box strategies while challenging moribund drug development protocols to bring new therapeutic relief to millions of people suffering with rare diseases. With a team of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus – Zevra intends to become a global leader in developing and commercializing treatments for rare diseases that have limited or no therapeutic options. The company’s recent Letter to Stockholders reveals what looks like a launch code for success and suggests the company is on a fast track to drive value for all its stakeholders – patients and caregivers, stockholders, investors, and employees.
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQZVRA) on behalf of Zevra stockholders. Our investigation concerns whether Zevra has violated the federal securities laws and/or engaged in other unlawful business practices.
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQZVRA). The investigation concerns whether Zevra and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Companies Reporting Before The Bell • Universal Stainless (NASDAQUSAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
